Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty

NCT ID: NCT04294862

Last Updated: 2022-10-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-01
• Study Completion Date: 2022-06-29

Brief Summary

This study will investigate TNP-2092 distribution into joint tissues in participants undergoing a total hip arthroplasty (THA) or a total knee arthroplasty (TKA). Tissue distribution is the primary objective, and plasma pharmacokinetics (PK), safety, and tolerability are secondary objectives.

Detailed Description

This is a Phase 1, open-label study to evaluate the tissue distribution, plasma PK, safety, and tolerability after a single 300 mg intravenous (IV) dose of TNP-2092 administered before induction of anesthesia in adult participants undergoing THA or TKA. Sixteen patients who are scheduled to undergo primary THA or TKA will be enrolled.

The enrolled participants who meet the inclusion/exclusion criteria will receive the study intervention (a single 300 mg IV dose of TNP-2092) 2 hours before induction of anesthesia on Day 1. Tissue samples from bone and synovial fluid will be collected during surgery and analyzed for TNP-2092 and cefazolin concentrations. Plasma samples will be collected on Day 1 and Day 2 for PK analysis. Safety and tolerability information will be collected on Day 1 and Day 2 at the clinical center, on Day 7 by phone, and on Day 14 at a final follow-up visit.

Conditions

Prosthetic Joint Infection

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

TNP-2092 300mg IV

TNP-2092 for injection 100mg/vial, 300mg, BID, 1 dose

Group Type: EXPERIMENTAL

TNP-2092

Intervention Type: DRUG

TNP-2092 for injection 100mg/vial

Interventions

TNP-2092

TNP-2092 for injection 100mg/vial

Intervention Type: DRUG

Other Intervention Names

CBR-2092

Eligibility Criteria

Inclusion Criteria

1. Male or females, 18 years of age or older

2. Participants who require primary THA or TKA

3. Body mass index (BMI) >=18 kg/m2 but <=40 kg/m2

4. Capable of giving signed informed consent

Exclusion Criteria

1. History or hypersensitivity or intolerability to any of the following drugs: any member of fluoroquinolones, rifamycin, cefazolin or TNP-2092

2. History of known methicillin-resistant Staphylococcus aureus (MRSA) infections

3. Presence of any surgical or medical condition that in the opinion of the principal investigator and the medical monitor that could impact the interpretation of the results of the study;

4. Evidence of significant hepatic, hematologic or immunologic disease;

5. History or evidence of severe renal disease

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

TenNor Therapeutics Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Rothman Orthopedic Institute

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

PJI001-04

Identifier Type: -

Identifier Source: org_study_id